PT  - JOURNAL ARTICLE
AU  - Sarkar, Rakesh
AU  - Lo, Mahadeb
AU  - Saha, Ritubrita
AU  - Dutta, Shanta
AU  - Chawla-Sarkar, Mamta
TI  - S glycoprotein diversity of the Omicron Variant
AID  - 10.1101/2021.12.04.21267284
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.04.21267284
4099  - http://medrxiv.org/content/early/2021/12/05/2021.12.04.21267284.short
4100  - http://medrxiv.org/content/early/2021/12/05/2021.12.04.21267284.full
AB  - On the backdrop of ongoing Delta variant infection and vaccine-induced immunity, the emergence of the new Variant of Concern, the Omicron, has again fuelled the fears of COVID-19 around the world. Currently, a very little information is available about the S glycoprotein mutations, transmissibility, severity and immune evasion behaviour of the Omicron variant. In the present study, we have performed a comprehensive analysis of the S glycoprotein mutations of 309 strains of the Omicron variant and also discussed the probable effects of observed mutations on several aspects of virus biology based on known available data of mutational effects on S glycoprotein structure, function, and immune evasion characteristics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors